Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Respiratory

Set Alert for Respiratory

Amgen Expects Quick, Broad Adoption Of Tezspire In Severe Asthma

Company says new asthma drug partnered with AstraZeneca will offer a new therapy option for severe patients with low eosinophil counts. The firms will provide launch plans in January.

Approvals Business Strategies

AstraZeneca And BenevolentAI Advance AI Partnership With Second Novel Target

AstraZeneca and BenevolentAI claim their partnership is augmenting and accelerating validation of new drug targets.

Respiratory Renal

AstraZeneca Rejigs Respiratory Franchise With Fresh Covis Deal

Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.

Respiratory Business Strategies

BI Bets On Gene Therapy To Treat All Cystic Fibrosis Patients

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Oxford BioMedica aim to get their CFTR gene therapy into the clinic soon, confident it could offer a long-lasting option for patients with cystic fibrosis.

Gene Therapy Manufacturing

Apnimed Moves Closer To Phase III With Sleep Apnea Drug

Apnimed is going to conduct one more Phase II study in sleep apnea, mainly to assess subjective endpoint questionnaires, and then hopes to launch a Phase III program by autumn of 2022.

Clinical Trials Drug Approval Standards

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; J&J adds pace to RSV vaccine race; Sarepta leapfrogs Pfizer in DMD gene therapy; and how real-world evidence and randomized trials might go together.

Biologics Clinical Trials

Providence’s COVID-19 mRNA Vaccine Challenger Seen In Phase III In Q1

A possible alternative to Pfizer and Moderna’s COVID-19 vaccines, Providence Therapeutics’ mRNA candidate is seen moving into Phase III trials during the calendar first quarter of next year. While partners Everest Medicines and Biological E have kept the ball rolling, the Canadian biotech will seek further funding, CEO Brad Sorenson tells Scrip in this audio interview.

Coronavirus COVID-19 Vaccines

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the prospects for Merck’s Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma’s president.

Commercial Companies

UK Travel Rule Sparks Row As India Seeks To Resume COVID-19 Vaccine Diplomacy

As India gets set to resume COVID-19 vaccine diplomacy from October, a new rule which will require Indians visiting UK who are fully vaccinated with AstraZeneca partner Serum Institute’s vaccine to undergo quarantine has sparked a row. Meanwhile, Indian companies await a nod from the WHO for wider acceptance of their COVID-19 vaccines.

Policy Coronavirus COVID-19

AstraZeneca Eyes Opportunity To Transform Asthma Rescue Treatment

The company plans to file PT027, a new fixed-dose combination of albuterol and budesonide, in 2022 following two positive Phase III trials showing a benefit on lung function.

Respiratory Clinical Trials

Amgen And AstraZeneca Tout Fresh Tezepelumab Data

Recently-submitted tezepelumab reduced the annualized asthma exacerbation rate by 86% in a subgroup of patients with severe, uncontrolled asthma and nasal polyps, according to data presented at the European Respiratory Society congress.

Respiratory Clinical Trials

Polyphor Pulled Out Of The Mire With EnBiotix Merger

Just over three years, Polyphor's initial public offering in Switzerland raised CHF165m. Now, with just enough cash to get through the third quarter, it has been saved by a deal with US biotech EnBiotix.

M & A Rare Diseases
See All
UsernamePublicRestriction

Register